Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ozan Aricak"'
Autor:
Asaf Dan, Ozan Aricak, Konstantinos Rounis, M. Angeles Montero-Fernandez, Ricardo Guijarro, Simon Ekman, Cristian Ortiz-Villalón, Luigi De Petris
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionProgrammed death ligand – 1 (PD-L1) expression is a well-established predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). Programmed death – 1 (PD-1) serves as the target protein to PD-L1 and their interaction
Externí odkaz:
https://doaj.org/article/6bc2bad02c314212b6aa290293416a85
Autor:
Demi Brownlie, Andreas von Kries, Giampiero Valenzano, Nicole Wild, Emel Yilmaz, Jesper Säfholm, Mamdoh Al-Ameri, Evren Alici, Hans-Gustaf Ljunggren, Igor Schliemann, Ozan Aricak, Felix Haglund de Flon, Jakob Michaëlsson, Nicole Marquardt
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTLung cancer is a leading cause of cancer-related death worldwide. Despite recent advances in tissue immunology, little is known about the spatial distribution of tissue-resident lymphocyte subsets in lung tumors. Using high-parameter flow cyt
Externí odkaz:
https://doaj.org/article/000ae8fd19714447920bbd41b44f02c9
Autor:
Junya Fukuoka, Kati Lindström, Felix Alarcón, Ozan Aricak, Ricardo Guijarro, Cristian Ortiz-Villalón, Hoa H.N. Pham, Oscar Grundberg, Akira Yoshikawa, Luigi De Petris, Anja C. Roden, M. Angeles Montero, Loránd L. Kis, Richard Attanoos
Publikováno v:
Annals of Diagnostic Pathology. 51:151701
PD1/PD-L1 pathway targeting therapies are nowadays an established treatment option for patients with NSCLC. We assessed whether PD-L1 expression in NSCLC tumor cells was associated with specific clinical features or overall survival using four differ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c34a51954b0814ee5db6ba28febe10e5
https://doi.org/10.1016/j.anndiagpath.2021.151701
https://doi.org/10.1016/j.anndiagpath.2021.151701